RecruitingNCT03549858
Patient Reported Outcomes Burdens and Experiences - Phase 3
Patient Reported Outcomes Burdens and Experiences (PROBE) - Phase 3 - Longitudinal Data Collection
Sponsor
McMaster University
Enrollment
1,000 participants
Start Date
Jan 1, 2018
Study Type
OBSERVATIONAL
Conditions
Summary
The PROBE Phase-3 study will collect data on patient reported outcomes, burdens, and experiences in patients living with hemophilia. The investigators will perform comparisons among countries, within country over time, within country against national normative data.
Eligibility
Inclusion Criteria2
- PWH will be recruited through national hemophilia patient organizations utilizing their existing membership rosters, social media outlets and meetings / events. The investigators are not proposing a pre-determined method of PWH recruitment. They will utilize the information acquired in the workshop and take-home project to inform best practice in recruitment methodology for the study. The investigators may consider requesting different countries test different PWH recruitment strategies to test reproducibility.
- In the future, the questionnaire might also be administered to patients with other chronic conditions.
Exclusion Criteria1
- Disease severity and Age bands or age limits (e.g. ≥ Age 18) may be utilized to narrow the study population.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERQuality of life measure (survey)
The QoL tool is a questionnaire
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03549858
Related Trials
Testing the Feasibility of a Self-Management Support Program for Patient With Chronic Diseases in Israel
NCT073677501 location
Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry
NCT069920762 locations
Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients
NCT0692204518 locations
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
NCT0728546021 locations
ATHNdataset Registry
NCT068205151 location